Advertisement

Topics

Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

22:14 EDT 25th April 2017 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 17,000+

Extremely Relevant

Adjuvant Bevacizumab for Colorectal Cancer?

Adding bevacizumab to capecitabine did not improve survival for patients with stage III or high-risk stage II disease.


Colorectal Cancer: Isofol’s Modufolin Could Change Mainstay Therapy

Decades-long academic and pharma research to improve on the benefits of the 5-fluorouracil and Leucovorin combination in colorectal cancer has...   

Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells


Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

FDA approves bevacizumab with chemotherapy for platinum-sensitive ovarian cancer

The U.S. Food and Drug Administration (FDA) has approved bevacizumab, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by bevacizumab alone, for the treatment of patients with...

Adjuvant Bevacizumab for Operable Gastroesophageal Cancer

Adding bevacizumab to perioperative chemotherapy failed to improve survival.

Study paves way to develop noninvasive diagnostic test for colorectal cancer

The type of bacteria in your gut may help diagnose colorectal cancer. Researchers at Baylor College of Medicine and other institutions have identified specific types of bacteria that seem to be abundant in individuals with colorectal cancer.

Colorectal Diseases Biobank links genetics and colorectal cancer

What if your family's DNA could become the blueprint for your very own precise and personalized treatment for colorectal cancer? Or, better yet, what if it could be used to help doctors screen you earlier for the disease, before it has a chance to strike?

Liquid Biopsy and Colorectal Cancer

A liquid biopsy option for potential colorectal cancer patients. Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. When diagnosed early, before cancer has spread, the relative five-year survival rate for CRC is 90%, but only approximately four out of 10 CRC cases [...]

Early detection of colorectal cancer can save lives

Colorectal cancer is the second leading cause of cancer death for men and women in the United States according to the American Cancer Society.

Medical News Today: Colorectal cancer screening initiative shows promise

The Ohio State University have trialed a colorectal cancer screening initiative for relatives of colorectal cancer patients. The results are promising.

Genetic Factors and Colorectal Cancer: Know Your Risk

Colorectal cancer is one of several cancers with known genetic risk factors. Because these known factors can be identified through genetic testing, it’s important to understand your risks and to discuss them with your healthcare provider. The following are three hereditary factors that can increase your risk for colorectal cancer: People with a personal or […] The post Genetic Factors and ...

CHARTA Shows Survival Benefit of Four-Drug Regimen for Advanced CRC

This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.

Bevacizumab for Extensive-Stage Small-Cell Lung Cancer

Adding bevacizumab to cisplatin and etoposide improved progression-free survival, but not overall survival, the primary outcome.

Sessile Serrated Polyps and Colorectal Cancer

To the Editor The comprehensive review by Dr Lieberman and colleagues addressed evolving issues in the field of colorectal cancer screening. However, I take issue with the brief discussion of serrated polyps and their effect on the practice of colorectal cancer screening.

Technology advances help to prevent, lessen impact of colon cancer

Approximately 140,000 people are diagnosed with colorectal cancer in the U.S. each year. March is Colorectal Cancer Awareness Month.

Colorectal cancer statistics, 2017

(American Cancer Society) Despite dramatic reductions in overall colorectal cancer incidence and mortality, striking disparities by age, race, and tumor subsite remain

FDA Approves Avastin® (Bevacizumab) Plus Chemotherapy for Treatment of Advanced Ovarian Cancer

Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Women are said to...

Follow-up of Positive Fecal Test Results

A large body of research demonstrates that colorectal cancer screening is an effective method for reducing colorectal cancer mortality. Screening can detect cancer at an earlier stage, before it becomes symptomatic, and the detection and removal of adenomas can prevent cancer. Rates of colorectal cancer screening had increased until 2010, at which time approximately 60% of eligible US adults parti...

Metastatic Colorectal Cancer: Does Exercise Matter?

Patients with colorectal cancer may be able to lower the risk of the disease worsening and improve their chances of survival with moderate daily exercise, according to new research by investigators at Dana-Farber Cancer Institute. The results of the research contradict the widespread belief that, because the prognosis for patients with metastatic cancer is often poor, […] The post Metastati...

New model paves way for immune therapies against colorectal cancer

About 95 percent of colorectal cancers are considered "microsatellite stable" and very few of these cancers respond to immunotherapy, meaning that the vast majority of metastatic colorectal cancer patients are unable to benefit from medicines that activate the immune system against the disease - a strategy that has helped dramatically extend the lives of patients with related cancers. A study pres...

Metabolite that promotes cancer cell transformation and colorectal cancer spread identified

Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial–mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread. The finding highlights the value of targeting D-2HG to establish new therapeutic approaches against...

AACR: New model paves way for immune therapies against colorectal cancer

(University of Colorado Anschutz Medical Campus) Study presented at AACR 2017 describes a new 'humanized mouse' model of colorectal cancer, allowing researchers to test new drugs and new drug combinations against the disease and potentially opening the door to immunotherapy for the larger, microsatellite-stable population of colorectal cancer patients.

Dramatic Rise in Colorectal Cancer in Younger Adults

Colorectal cancer rates have risen dramatically among Generation Xers and millenials; researcher warns that repeal of the Affordable Care Act is 'very concerning' for cancer diagnosis. Medscape Medical News


Quick Search
Advertisement
 

News Quicklinks